Patent · US Active

Biomarkers for the diagnosis of ALS

US8465727B2 · kind B2 · utility

2Cited by

0References

21Claims

0Family size

Assignee

University of Pittsburgh—Of the Commonwealth System of Higher Education · US

Inventor

Robert Bowser · Scottsdale, US

Key dates

Filing date	Oct 6, 2010
Grant date	Jun 18, 2013
Priority date	—
Expiry date	Jan 24, 2031

Classification

Technology area (CPC G)Physics
CPC primaryG01N2800/285
WIPO fieldMeasurement
WIPO sectorInstruments

Abstract

Methods for determining the onset of ALS in a subject are provided. One method includes analyzing a sample obtained from the subject for the presence or amount of one or more biomarkers indicative of ALS. In a preferred embodiment, the biomarkers are one or more of the following: C-reactive protein (CRP), cystatin c, plasminogen, complement C3, CysGly-transthyretin, and phosphorylated neurofilament heavy chain (pNFH). The sample is typically cerebral spinal fluid (CSF). The levels or concentrations of the biomarkers can be used to determine the onset of ALS, monitor the progression of ALS, or monitor the progression of a treatment for ALS.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.